Back

Time to event analysis in patients managed on rivaroxaban while taking concurrent interacting medications (CIM)

25 August 2018 (11:00 - 16:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - Antiplatelet and anticoagulant drugs Anticoagulants ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Jeffrey Michel

Baylor Scott and White Health, Austin (United States of America)

5 More presentations in this session

Presentation thumbnail
Doctor T. Petroni (Montauban, FR)
Abstract
Presentation thumbnail
Associate Professor M. Klinceva (Skopje, MK)
Abstract Slides
Presentation thumbnail
Mrs A. Kosinova (Elvas, PT)
Abstract Slides
Presentation thumbnail
Professor R. Rosenson (New York City, US)
Abstract Slides
Presentation thumbnail
Doctor A. Almaghraby (Ras Al Khaimah, AE)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 1 - Antiplatelet and anticoagulant drugs

The Event

Event poster

ESC Congress 2018

25 August 2018 11:00 CET
You may be interested in
thumbnail
Congress Presentation
Drug-drug interactions of NOACs with comedication: prevalence and implications for adverse events in patients with atrial fibrillation
13 April 2026
thumbnail
Congress Presentation
Effectiveness and safety of apixaban, low-molecular weight heparin, and warfarin among high-risk subgroups of venous thromboembolism patients with active cancer
28 August 2020
thumbnail
Congress Presentation
Rivaroxaban dosing in patients with atrial fibrillation: results from the RIVER registry- is dosing according to renal function appropriate?
27 August 2021
thumbnail
Congress Presentation
Efficacy and safety of low-dose rivaroxaban on top of aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial
30 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources